Search Results - Therapeutic

48 Results Sort By:
G9a inhibition decreases stress-induced escalation of alcohol drinking
Technology: Inventors at MUSC have identified that NAc (nucleus accumbens) G9a is requiredfor stress-regulated drinking in both ethanol-dependent and non-dependent animals.Importantly they discovered that treating mice with UNC0642 (an inhibitor of G9a) in a stressinducedethanol drinking assay (Figure. 1A) showed significant reduction in ethanol consumptionduring...
Published: 6/3/2021   |   Inventor(s): Ethan Anderson, Christopher Cowan
Keywords(s):  
Category(s): Therapeutic
CaMKK-β as a target for prevention of noise- and aminoglycoside-induced hearing loss
Compositions and Methods for Attenuation of Hearing Loss Technology: Researchers at MUSC have developed a biopharmaceutical therapy that reduces the expression of specific proteins associated with both noise and chemically induced hearing loss. The invention provides a gene therapy and therapeutic target for prevention of acquired hearing loss. Previous...
Published: 5/5/2021   |   Inventor(s): Su-Hua Sha
Keywords(s):  
Category(s): Therapeutic
Monobody R15 targets the nucleotide free state of RAS to block oncogenic signaling and transformation
Technology: Researchers at MUSC and NYU Langone Medical Center have identified a synthetic protein (R15) that selectively binds to the nucleotide-free state of the RAS proto-oncogene (apoRAS) and is the first experimental tool to selectively inhibit the signaling and oncogenic activity of selected oncogenic RAS mutants (Figure 1). The synthetic protein...
Published: 3/26/2021   |   Inventor(s): John O'Bryan, Shohei Koide, Akiko Koide
Keywords(s):  
Category(s): Therapeutic
Recombinant fusion proteins and complement inhibitors targeting P-selectin, and therapeutic and diagnostic application
Technology: Inventors at MUSC have designed fusion proteins to treat inflammatory and other related pathologies by binding p-selectin (PSel) and modulating complement. Although targeting complement has shown great promise in treating numerous pathologies which has also led to the approval of multiple drugs (e.g. eculizumab, Berinert, Cinryze), targeting...
Published: 2/16/2021   |   Inventor(s): Stephen Tomlinson, Ali Alawieh, Pablo Engel
Keywords(s):  
Category(s): Therapeutic
Advancements of 599 peptide carrier design through stereochemical and/or amino acid modifications
Technology: Researchers at MUSC have developed a cell-penetrating peptide (CPP) specifically designed to overcome challenges associated with small interfering RNA (siRNA)-drug delivery for cancer treatment. Investigators previously generated the 599 peptide that silenced the CIP2A oncogene and suppressed tumor growth in vivo (Figure 1). Figure...
Published: 1/28/2021   |   Inventor(s): Andrew Jakymiw, Charles Holjencin
Keywords(s):  
Category(s): Therapeutic
N-aroylanthranilic acids and derivatives as inhibitors of bacterial class B transpeptidases
Technology: MUSC inventors identified a new chemical scaffold (N-aroylanthranilic acids and derivatives) as inhibitors of various class B penicillin-binding proteins (PBPs). The novel molecules showed high potency of PBP inhibition. Antimicrobial assays against antibiotic-resistant gonorrhea strain FA19 and H041 showed significant growth inhibition...
Published: 11/9/2020   |   Inventor(s): Jonathan Turner, Christopher Davies, Patrick Woster, Joy Kirkpatrick
Keywords(s):  
Category(s): Therapeutic
Motion-Activated, Closed-loop Non-invasive Vagus Nerve Stimulation as a Neurorehabilitation Tool
Technology: Surgeons and researchers at MUSC have created a non-invasive, motion-activated, closed-loop vagus nerve simulation (VNS) device that enhances neuroplasticity to accelerate motor restoration in post-stroke rehabilitation. The device couples VNS with limb motion to provide stimulation simultaneously with movement, enhancing the effects of...
Published: 10/22/2020   |   Inventor(s): Bashar Badran, Mark George
Keywords(s):  
Category(s): Therapeutic
CD38 mediated metabolic axis in anti-tumor T cell immunotherapy
Technology: MUSC researchers have identified T cells with reduced surface expression of NADase CD38 exhibited intrinsically higher NAD+ levels, enhanced oxidative phosphorylation, higher glutaminolysis and altered mitochondrial dynamics that vastly improved tumor control. Inventors identified combining the culture conditions of Th17ILβ+TGFβ...
Published: 10/22/2020   |   Inventor(s): Shikhar Mehrotra, Shilpak Chatterjee
Keywords(s):  
Category(s): Therapeutic
Click Chemistry Probes for Specific Targeting of Sialic Acid Tumor Antigens
Technology: Researchers at MUSC have identified methods for selectively modifying linked sialic acid or polysialic acid with bioorthagonal reaction schemes having applications broad applications in drug delivery. This is achieved by exposing a 2,3 linked sialic acid and/or a 2,8 linked polysialic acid to condensing reagents under suitable reaction conditions....
Published: 10/19/2020   |   Inventor(s): Richard Drake, Xiaowei (Vivian) Lu
Keywords(s):  
Category(s): Therapeutic
Asymmetric Dimethylarginine (ADMA) as a Bio-marker for Early-Stage Diagnostic of Cerebrovascular Diseases
Technology: MUSC researchers have identified Asymmetric Dimethylarginine (ADMA) as a novel early-stage biomarker to diagnose brain vascular pathologies associated with Alzheimer’s disease (AD), vascular cognitive impairment and dementia (VCID), and multiple sclerosis (MS). Data gathered shows that Tg-SwDI mice, the most common model for AD-associated...
Published: 4/9/2020   |   Inventor(s): Inderjit Singh, Avtar Singh
Keywords(s):  
Category(s): Therapeutic
1 2 3 4 5 
© 2021. All Rights Reserved. Powered by Inteum